Pharmacogenetic Study in Patients Received Iron Chelating Agent

Status Completed

Clinical Trial Summary

To investigate effect of genetic variations on the toxicities and find optimal target population, the investigators planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase.

Clinical Trial Description

Transfusion-associated iron overload induces systemic toxicity. Recently, deferasirox, a convenient long acting oral agent, has been introduced in clinical practice with promising efficacy. However, some patients experience drug-related toxicities and cannot tolerate it. To investigate effect of genetic variations on the toxicities and find optimal target population, we planned to analyze the genetic polymorphisms of UDP-glucuronosyltransferase 1A (UGT1A) subfamily, multi-drug resistance-associated protein 2 (MRP2) and breast cancer resistance protein (BCRP) among pediatric patients received deferasirox. ;

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Hemosiderosis

Clinical Trial Details

NCT number	NCT01623895
Study type	Observational
Source	Seoul National University Hospital
Contact
Status	Completed
Phase	N/A
Start date	December 2007
Completion date	June 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00171171` - A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis	Phase 3
Completed	`NCT00303329` - Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients	Phase 2
Completed	`NCT00469560` - Safety, Tolerability, and Efficacy of Deferasirox in MDS	Phase 3
Completed	`NCT00171301` - Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)	Phase 4
Completed	`NCT01516853` - Non-invasive Quantification of Liver Iron With MRI
Terminated	`NCT04284371` - The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) Pediatric Patients
Completed	`NCT00105495` - Efficacy Study in Removing Excess Iron From the Heart	Phase 4
Enrolling by invitation	`NCT02025543` - Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content